Public consultation on applications to be considered by the MSAC (April 2024)

Overview

Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 4-5 April 2024.  

MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.   

It is anticipated that the below-mentioned applications will proceed to MSAC in April 2024. Consultation input must be received by no later than Friday, 16 February 2024 for it to be considered by MSAC. A consultation survey form is available on the relevant application webpage.

Further information on MSAC’s consultation process is also available on the MSAC website.

Applications scheduled to be considered:

1523.1 - Transluminal insertion, management, repositioning and removal of intravascular microaxial blood pump (Impella) for patients requiring mechanical circulatory support

1662.2 - The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques

1677.1 - Pharmacy Diabetes Screening Trial (PDST)

1686.1 - ¹⁷⁷ Lutetium PSMA i&t for metastatic castrate resistant prostate cancer

1708 - RNA PCR testing to determine eligibility and treatment for PBS-subsidised bulevirtide (HEPCLUDEX) for treatment of Hepatitis Delta Virus

1712 - Out-of-laboratory Sleep Studies in the Diagnosis and Management of Sleep Disordered Breathing in Children & Adolescents

1713 - Cardiac MRI in the diagnosis of myocarditis

1720 - ⁶⁸Ga PSMA-11 PET/CT imaging for patients who are candidates for PSMA targeted therapy

1722.1 - Axicabtagene ciloleucel (YESCARTA®) for relapsed or refractory large B-cell lymphoma

1741 - Continuous Nerve Blockade using a catheter technique

1749 – Insertion of durable ventricular assist device (VAD) for use as destination therapy

1758 - Expansion of MBS item numbers 12320 & 12322 for bone mineral density (BMD) testing to include patients aged 60-69 years

1764 - Micro-bypass glaucoma surgery device implantation into the suprachoroidal space as a standalone procedure in patients with open angle glaucoma

Application 1765 - Request to amend existing MBS items 73303 and 73304 (BRCA1/2 mutation testing in patients with metastatic castration resistant prostate cancer) to add talazoparib

What happens next

Once the consultation closes, submissions will be compiled and considered by MSAC.

Once it has finalised its appraisal of an application for public funding, MSAC publishes a Public Summary Document (PSD). The PSD captures MSAC deliberations and key advice to the Minister, which is generally to either support funding; not support funding; or defer consideration. 

PSDs are generally published approximately three (3) months after the MSAC meeting at which the application was considered. The PSD can be located on the relevant application webpage on the MSAC website.